Search Results

Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I

Authors: Berger, Marc L.; Mamdani, Muhammad; Atkins, David; Johnson, Michael L.

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1044-1052(9)

Publisher: Blackwell Publishing

Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II

Authors: Cox, Emily; Martin, Bradley C.; Van Staa, Tjeerd; Garbe, Edeltraut; Siebert, Uwe; Johnson, Michael L.

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1053-1061(9)

Publisher: Blackwell Publishing

The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report

Authors: McGhan, William F.; Al, Maiwenn; Doshi, Jalpa A.; Kamae, Isao; Marx, Steven E.; Rindress, Donna

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1086-1099(14)

Publisher: Blackwell Publishing

Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region

Authors: Yang, Bong-min; Lee, Kenneth

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S1-S2(1)

Publisher: Blackwell Publishing

The Current Capacity and Future Development of Economic Evaluation for Policy Decision-Making: A Survey among Researchers and Decision-Makers in Thailand

Authors: Chaikledkaew, Usa; Lertpitakpong, Chanida; Teerawattananon, Yot; Thavorncharoensap, Montarat; Tangcharoensathien, Viroj

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S31-S35(1)

Publisher: Blackwell Publishing

Adjusting for health-related QOL does not appear to substantially affect cost per life year (LY) ratios for most cancer studies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 6-6(1)

Publisher: Adis International

Economic analyses of aromatase inhibitors that are sponsored by pharmaceutical companies are less likely to report unfavourable results

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 13-13(1)

Publisher: Adis International

Biosimilars of tumour necrosis factor-α (TNF-α) inhibitors will erode $9.6 billion in brand sales

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

Gastric cancer drug market to grow through targeted therapies

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 14-14(1)

Publisher: Adis International

China to cut prices on over 2300 essential medicines

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 590, 2009-10-31 , pp. 10-10(1)

Publisher: Adis International

A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US

Author: Tunis, Sandra L.

Source: PharmacoEconomics, Volume 27, Number 9, 1 September 2009 , pp. 735-744(10)

Publisher: Adis International

Leading pharmaceutical markets in Latin America are set to grow by 9.9% per annum on average till 2014

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 587, 2009-09-19 , pp. 9-9(1)

Publisher: Adis International

Varenicline takes the top spot in Belgium

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 588, 2009-10-03 , pp. 9-9(1)

Publisher: Adis International

Novel obesity drugs, oncology biosimilars to impact markets

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 588, 2009-10-03 , pp. 11-11(1)

Publisher: Adis International

Pharmacoeconomics: principles and relevance to the activities of drug and therapeutics committees

Authors: Hughes, Dyfrig; Reynolds, D John M

Source: Clinical Medicine, Journal of the Royal College of Physicians, Volume 9, Number 5, September 2009 , pp. 490-492(3)

Publisher: Royal College of Physicians

Depression, SLE and diabetes drug markets set for growth

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 586, 2009-09-05 , pp. 10-10(1)

Publisher: Adis International

China has released its first ever list of essential medicines which includes 200 western drugs

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 586, 2009-09-05 , pp. 11-11(1)

Publisher: Adis International

Principles and methodology for translation and cross-cultural adaptation of the Nordic Occupational Skin Questionnaire (NOSQ-2002) to Spanish and Catalan

Authors: Sala-Sastre, Nohemi; Herdman, Mike; Navarro, Lidia; de laPRADA, Miriam; Pujol, RAMÓNM.; Serra, Consol; Alonso, Jordi; Flyvholm, Mari-Ann; GIMÉNEZ-Arnau, AnaM.

Source: Contact Dermatitis, Volume 61, Number 2, August 2009 , pp. 109-116(8)

Publisher: Blackwell Publishing

Pharmacoeconomic Considerations in Treating Actinic Keratosis

Authors: Neidecker, Marjorie V.; >Mary Lynn Davis-Ajami,; Balkrishnan, Rajesh; Feldman, Steven R.

Source: PharmacoEconomics, Volume 27, Number 6, 6 June 2009 , pp. 451-464(14)

Publisher: Adis International

Cost effective analysis of ribosome-component immune modulation

Authors: Fiocchi, Alessandro; Olivieri, Dario; Marcassa, Sergio; Zava, D.; Robberto, Elisa

Source: Allergy and Asthma Proceedings, Volume 30, Supplement 1, July/August 2009 , pp. S37-S39(1)

Publisher: OceanSide Publications, Inc